<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394975</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-036-Ⅲ-RCC</org_study_id>
    <nct_id>NCT04394975</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer</brief_title>
  <official_title>A Phase III, Randomized, Open-label, Active Controlled, Multicenter Study on Toripalimab Combined With Axitinib Versus Sunitinib Monotheraphy as a First-Line Treatment for Unresectable or Metastatic Renal Cell Carcinoma (RCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, controlled, multicenter, phase III trial to compare the&#xD;
      efficacy and safety of Toripalimab in combination with axitinib to sunitinib monotherapy as a&#xD;
      first-line therapy for advanced RCC. Eligible patients will be randomized 1:1 to receive the&#xD;
      combination therapy of Toripalimab and axitinib or sunitinib monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS assessed by IRC per RECIST 1.1.</measure>
    <time_frame>3 years</time_frame>
    <description>To compare the progression-free survival (PFS) per response evaluation criteria in solid tumors (RECIST) 1.1 as assessed by independent review committee (IRC) in subjects treated with Toripalimab plus axitinib vesus sunitinib monotherapy as a first-line treatment for advanced RCC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS assessed by investigators per RECIST 1.1;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR assessed by investigators and IRC per RECIST 1.1, respectively;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR, assessed by investigators and IRC per RECIST 1.1, respectively;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR assessed by investigators and IRC per RECIST 1.1, respectively;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rate assessed by investigators and IRC per RECIST 1.1, respectively;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS assessed by investigators and IRC per RECIST 1.1, respectively;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and grade of AEs and SAEs per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, incidence of ≥ grade 3 AE;</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and grade of AEs and SAEs related to study drugs per NCI-CTCAE version 5.0, AEs ≥ grade 3 related to the study drugs.</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarker</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation between biomarker (PD-L1) and the efficacy of Toripalimab</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toripalimab+axitinib combination therapy. Participants receive Toripalimab 240mg intravenously every 3 weeks plus axitinib 5mg orraly twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sunitinib will be administered 50mg QD orally according to label recommendation (4 consecutive weeks followed by a 2-week off-treatment period,or 2 consecutive weeks followed by a 1-week off-treatment period), until treatment criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Biological : Toripalimab Drug: Axitinib</intervention_name>
    <description>Biological: Toripalimab, Intravenous infusion Drug: Axitinib, oral tablet</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>Drug: Sunitinib, oral capsule</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Fully understand and be willing to provide written informed consent.&#xD;
&#xD;
          2. Male or female with age ≥ 18 years and &lt;80 years.&#xD;
&#xD;
          3. Have received no prior systemic therapy after previous metastasis for RCC,&#xD;
             histologically confirmed diagnosis of unresectable, recurrent or metastatic RCC with&#xD;
             clear cell component with or without sarcomatoid features,Prior cytokine therapy was&#xD;
             allowed.&#xD;
&#xD;
          4. The IDMC score was medium to high risk.&#xD;
&#xD;
          5. Having at least one measurable disease per RECIST 1.1. Lesions situated in a&#xD;
             previously irradiated area are considered measurable if re-progression has been&#xD;
             demonstrated.&#xD;
&#xD;
          6. Provide archival tumor tissues or newly obtained biopsies if patients participate in&#xD;
             the exploratory study.&#xD;
&#xD;
          7. ECOG PS 0 or 1.&#xD;
&#xD;
          8. Adequate function of vital organs:&#xD;
&#xD;
        Bone marrow function (without blood or blood products transfusion, without hematopoietic&#xD;
        stimulating factor or other medication to improve blood cell count within 2 days prior to&#xD;
        first dose of study drug):&#xD;
&#xD;
        Absolute neutrophil count (ANC) ≥ 1.5×109/L. Platelets ≥ 100×109/L. Hemoglobin ≥ 9.0g/dL or&#xD;
        ≥ 5.6mmol/L.&#xD;
&#xD;
        Renal function:&#xD;
&#xD;
        Serum creatinine ≤ 1.5×ULN&#xD;
&#xD;
        Hepatic function:&#xD;
&#xD;
        Serum total bilirubin ≤1.5×ULN or total bilirubin levels &gt;1.5×ULN with direct bilirubin ≤&#xD;
        ULN. AST and ALT ≤2.5 × ULN, ≤5×ULN in those with hepatic metastasis.&#xD;
&#xD;
        Endocrine function:&#xD;
&#xD;
        Normal thyroid stimulating hormone, or abnormal TSH whilst normal FT3 and FT4.&#xD;
&#xD;
        Coagulation function:&#xD;
&#xD;
        International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN, and activated&#xD;
        partial thromboplastin time (aPTT) ≤1.5×ULN, Subjects receiving anticoagulant therapy&#xD;
        (e.g., heparin or warfarin) may participate in the study with PT or aPTT levels within the&#xD;
        scope of the proposed therapy and monitored during study treatment.Left ventricular&#xD;
        ejection fraction (LVEF) ≥ 50%.&#xD;
&#xD;
        8. Being willing and able to comply with scheduled visits, treatment plan, laboratory tests&#xD;
        and other study procedures.&#xD;
&#xD;
        10. Female subjects of childbearing potential must have a negative serum pregnancy test&#xD;
        within 7 days prior to the first treatment dose. Female subjects of childbearing potential&#xD;
        and male subjects whose partners are of childbearing potential must agree to use a highly&#xD;
        effective methods of contraceptive throughout the study and for 180 days after the last&#xD;
        dose of study therapy.&#xD;
&#xD;
        Exclusion criteria:Bone marrow functiPatients with any of the following conditions will not&#xD;
        be included in the study:&#xD;
&#xD;
          1. PriorAnti-PD-1, PD-L1 or CTLA-4 agents ).&#xD;
&#xD;
          2. Prior systemic anti-cancer therapy after metastasis (e.g., VEGF/VEGFR or mTOR&#xD;
             targeting agents, including (but not limited to) sunitinib, axitinib, sorafenib,&#xD;
             pazopanib, cabozantinib, lenvatinib, bevacizumab or everolimus.&#xD;
&#xD;
          3. Progression or recurrence during neoadjuvant/adjuvant therapy for renal cell cancer or&#xD;
             within 12 months after the last dose treatment.&#xD;
&#xD;
          4. Has participated or is currently participating in a trial of investigational agent&#xD;
             within 4 weeks prior to the first dose of study treatment, unless observational&#xD;
             (non-interventional) clinical study or follow-up period of interventional study.&#xD;
&#xD;
          5. Had major surgery (judged by investigators) within 4 weeks prior to the first dose of&#xD;
             study treatment or has not recovered from prior surgery.&#xD;
&#xD;
          6. Has traditional Chinese medicine or Chinese patent medicine preparation with&#xD;
             anti-cancer indication within 2 weeks prior to the first dose of study treatment.&#xD;
&#xD;
          7. Requiring corticosteroids (Prednisone &gt;10 mg/day or equivalent analogue) or other&#xD;
             immunosuppressive agents within 2 weeks prior to the first dose of study treatment.&#xD;
             Patients without active autoimmune disease using inhaled prednisone &gt;10 mg/day will&#xD;
             not be excluded from the study.&#xD;
&#xD;
          8. Has a history of organ transplantation or required long-term treatment with&#xD;
             corticosteroids.&#xD;
&#xD;
          9. Hypothyroidism, hypoadrenalism or hypopituitarism that can be controlled only with&#xD;
             hormone replacement therapy, type I diabetes, psoriasis or leucoderma not requiring&#xD;
             systematic treatment.&#xD;
&#xD;
         10. Not recovered from the toxicity of prior anti-cancer therapy, i.e., not recovered to&#xD;
             baseline, Grade 0-1 (NCI-CTCAE 5.0, except alopecia) or per inclusion/exclusion&#xD;
             criteria in protocol. Under rational expectation, irreversible toxicities (e.g.,&#xD;
             hearing loss) which will not be worsened by study treatments may be enrolled in the&#xD;
             study.&#xD;
&#xD;
         11. Has an additional malignancy that has progressed or required treatment within 5 years&#xD;
             prior to randomization (basal cell carcinoma of the skin, squamous cell carcinoma of&#xD;
             the skin, superficial bladder cancer, or carcinoma in situ such as breast cancer,&#xD;
             prostate cancer are acceptable if they have undergone potentially curative&#xD;
             therapy；Remarks: Localized low-risk prostate cancer [ patietns with stage ≤ T2a,&#xD;
             Gleason score ≤ 6 and PSA &lt; 10ng/mL at the time of diagnosis (as measured) can be&#xD;
             included in this study if the subject has received radical therapy and has no evidence&#xD;
             for biochemical recurrence(PROSTATE specific antigen,PSA)].&#xD;
&#xD;
         12. Has a history of active central nervous system (CNS) metastasis or CNS metastasis had&#xD;
             been confirmed by radiological examination (MRI or CT) at baseline within 30 days&#xD;
             prior to the first dose of study drug.Subjects may participate who had been stable at&#xD;
             least for 3 months after prior surgery or RT for brain or meningeal metastasis and&#xD;
             discontinued systemic treatment with corticosteroids (Prednisone &gt;10 mg/day or&#xD;
             equivalent analogue) for at least 4weeks. Subjects may participate in the study if&#xD;
             their CNS metastases are adequately treated to meet the requirements specified in the&#xD;
             inclusion criteria, and their neurological symptoms recover to grade 0-1 (CTCAE 5.0)&#xD;
             for at least 2 weeks prior to inclusion (except for residual signs or symptoms&#xD;
             associated with CNS treatment).&#xD;
&#xD;
         13. Poorly controlled hypertension (systolic blood pressure ≥ 150mmHg and/or diastolic&#xD;
             blood pressure ≥ 90mmHg).&#xD;
&#xD;
         14. Presence of the following cardiovascular events within 6 months prior to&#xD;
             randomization:&#xD;
&#xD;
               1. Myocardial infarction&#xD;
&#xD;
               2. Unstable angina pectoris&#xD;
&#xD;
               3. Cardiac angioplasty or stent&#xD;
&#xD;
               4. Coronary/peripheral artery bypass graft&#xD;
&#xD;
               5. Grade III or IV congestive heart failure per New York Heart Association&#xD;
&#xD;
               6. Cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
         15. QT interval (QTc) ≥ 480 msec corrected with heart rate (Bazett's formula);&#xD;
&#xD;
         16. Has active hemorrhage or history of other significant hemorrhage episodes within 30&#xD;
             days prior to randomization.&#xD;
&#xD;
         17. Has deep vein thrombosis or pulmonary embolism within 6 months prior to randomization.&#xD;
&#xD;
         18. Has arterial thrombosis within 12 months prior to randomization.&#xD;
&#xD;
         19. Has clinically significant gastrointestinal (GI) abnormalities including:&#xD;
&#xD;
               1. Malabsorption, total gastrectomy or any other condition that might affect the&#xD;
                  absorption of orally taken medication.&#xD;
&#xD;
               2. Active ulcer under treatment in the past 6 months;&#xD;
&#xD;
               3. Active GI bleeding (e.g., hematemesis, hematochezia or melena) in the past 3&#xD;
                  months, and without evidence of resolution documented by endoscopy or&#xD;
                  colonoscopy.&#xD;
&#xD;
               4. Intraluminal metastatic lesion with suspected hemorrhage, inflammatory bowel&#xD;
                  disease, ulcerative colitis, GI perforation, or other GI conditions associated&#xD;
                  with increased risk of perforation.&#xD;
&#xD;
         20. Has a history of or current (non-infective) pneumonia/ interstitial lung disease that&#xD;
             required steroids.&#xD;
&#xD;
         21. Has an active infection requiring systemic therapy. Has a known history of Human&#xD;
             Immunodeficiency Virus (HIV) infection (HIV antibody positive), HBV or HCV infection&#xD;
             (Patients with positive HBsAg or negative HBsAg, but positive HBcAb will be enrolled&#xD;
             in the study when HBV DNA was tested in central laboratory and lower than ULN.&#xD;
             Patients with a history of HCV infection may participate in the study if the result of&#xD;
             HCV RNA test was negative during screening period).&#xD;
&#xD;
         22. Has received a live virus vaccine within 30 days prior to randomization, including&#xD;
             (but not limited to) mumps, rubella, measles, varicella/ herpes zoster (chicken pox),&#xD;
             yellow fever, rabies, Bacille Calmette-Guérin (BCG) and typhoid vaccine. Inactivated&#xD;
             virus vaccines are allowed.&#xD;
&#xD;
         23. Has a history of hypersensitivity reaction, including (but not limited to) antibodies&#xD;
             and TKIs.&#xD;
&#xD;
         24. Known history of psychiatric disorders or drug abuse.&#xD;
&#xD;
         25. Has evidence of inadequate wound healing.&#xD;
&#xD;
         26. Has current use (within 7 days of randomization) or anticipated need for treatment&#xD;
             drugs what are known strong CYP3A4/5 inhibitor and CYP3A4/5 inducer (including, but&#xD;
             not limited to, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin and St.&#xD;
             John's wort) or the drugs that are known with proarrhythmic potential (including, but&#xD;
             not limited to, terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol&#xD;
             and benazapril, etc.).&#xD;
&#xD;
         27. Has a history or current evidence on any condition, therapy or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with subject's participation&#xD;
             for the full duration of the study, or is not in the best interest of subject to&#xD;
             participate, in the opinion of investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fugui Wang</last_name>
    <phone>13511074153</phone>
    <email>fugui_wang@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo, MD, PhD</last_name>
      <phone>13911233048</phone>
      <email>guoj307@126.com</email>
    </contact>
    <investigator>
      <last_name>Jun Guo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

